����������

A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT  today. Responding to a recent  in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.